NCT07223411 2025-11-26
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
University of Pittsburgh
Recruiting
University of Pittsburgh
Instituto de Investigación Biomédica de Salamanca
IRCCS San Raffaele
Fondazione Policlinico Universitario Agostino Gemelli IRCCS